Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wilex AG

www.wilex.com

Latest From Wilex AG

Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed

A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.

StartUps and SMEs Financing

Deal Watch: Genentech Pays Big For Seragon’s Early Assets

Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.

BioPharmaceutical Deals

BioNotebook: PaxVax, Bluebird/Pregenen, RedHill/Wilex, CureVac/Sanofi Pasteur, Synchroneuron, Advanced Cell, Raptor, Ablynx

PaxVax has 1st Phase III success; Bluebird buys Pregenen; RedHill acquires Wilex asset; Sanofi options CureVac vaccine; Synchroneuron gets VC funding; and Advanced Cell, Raptor, Ablynx raise new cash.

Gastrointestinal Infectious Diseases

Merck Serono enters antibody drug conjugate fray

Merck Serono has expanded its oncology activities into antibody drug conjugates (ADCs) through a deal signed with Cambridge, Massachusetts-based Mersana Therapeutics.

Cancer Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Wilex Biotechnology GMBH
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Wilex AG
  • Senior Management
  • Jan Schmidt-Brand, PhD, CFO
    Andreas Pahl, Head, R&D
  • Contact Info
  • Wilex AG
    Phone: (49) 89 41 31 38 0
    Grillparzerstr. 10
    Munich, 81675
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register